Adial Pharmaceuticals is now Azora Therapeutics (NASDAQ: AZR). Read more →
Azora Therapeutics | Board of Directors

Board of Directors

Director

Matt Davidson, Ph.D.

Matt Davidson, Ph.D., is co-founder and Chief Executive Officer of Azora. Prior to Azora, he founded and served as Chief Executive Officer of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), a biotech company developing novel therapies for dermatological conditions including molluscum contagiosum and common warts. At Verrica, he developed the core technology and led the company through Phase 3 trials and an IPO to FDA approval of YCANTH® (cantharidin), the first approved treatment for molluscum contagiosum. He holds numerous patents spanning cantharidin chemistry and aryl hydrocarbon receptor (AhR) agonist therapeutics and was named a 2019 Biocom Catalyst Award recipient. Matt received his B.A. in molecular and cellular biology from UC Berkeley and his Ph.D. in Immunology at Stanford University’s School of Medicine.

Independent Director

Aida Habtezion, M.D.

Aida Habtezion, M.D., is an independent director of Azora Therapeutics. A physician-scientist in gastroenterology and immunology, she served as Chief Medical Officer and Head of Worldwide Medical & Safety at Pfizer, where she led global medical and patient-safety activities across the company’s portfolio of medicines and vaccines. Previously, she was a tenured Professor of Medicine and Associate Dean for Academic Affairs at Stanford University School of Medicine, where she directed an NIH-, DOD-, and foundation-funded translational research laboratory focused on immune mechanisms and therapeutic targets in intestinal and pancreatic inflammatory diseases. Her more than 100 peer-reviewed publications include work on the role of the aryl hydrocarbon receptor (AhR) in intestinal immunity, the same pathway Azora’s AT177 is designed to engage. She received her M.D. from McMaster University, completed internal medicine training at the University of Western Ontario and a gastroenterology and hepatology fellowship at the University of Toronto, followed by a postdoctoral research fellowship in gastroenterology and immunology at Stanford University, and holds an M.Sc. in nutritional sciences from the University of Guelph and a B.Sc. in chemistry from the University of Alberta.

Independent Director

Paul Hastings

Paul J. Hastings is Chief Executive Officer of Nkarta, Inc. He is also a Crohn’s Disease patient advocate passionate about advancing care in the inflammatory bowel disease community as well as Chair of the Board of Youth Rally Inc, a patient advocacy organization that serves the needs of teens with 54 diagnoses of the bowel and bladder, including Crohn’s disease and Ulcerative Colitis. He has led numerous biopharmaceutical companies as chief executive, including OncoMed Pharmaceuticals, QLT, Axys and LXR Biotechnology. He began his career at Hoffmann LaRoche, and then held a number of positions of increasing responsibility, including General Manager of Synergen Europe, President of Genzyme Europe and Genyme Therapeutics and President of Chiron Biopharmaceuticals. He currently serves as Chair of the board ofSpecific Biologics, a member of the board of EnGene, and the former chair of the Biotechnology Innovation Organization. He has served on several biotech boards, including being the Chair of Pacira Biosciences, Chair of the board of Proteolix (acquired by Onyx), a member of the boards at ViaCyte (acquired by Vertex), Relypsa (acquired by Galenica), and ViaCell (acquired by Perkin-Elmer).

Independent Director

Tom Soloway

Thomas Soloway is an independent director of Azora Therapeutics. He is a biopharmaceutical executive with decades of operating and capital-markets experience, and currently serves as the Chief Executive Officer of T-knife Therapeutics, a next-generation T-cell therapy company. He previously served in successive roles as Chief Financial Officer and Chief Operating Officer of Audentes Therapeutics, which he helped take public and guide through its acquisition by Astellas Pharma, and earlier as Senior Vice President and Chief Financial Officer of Ascendis Pharma. He has served on the boards of several public biotechnology companies, including Satsuma Pharmaceuticals and Third Harmonic Bio. He holds an M.B.A. from Georgetown University’s McDonough School of Business.

Independent Director

Wendy Young, Ph.D.

Wendy Young, Ph.D., is an independent director of Azora Therapeutics. A medicinal chemist and biotech leader with more than 30 years in drug discovery, she built and led Genentech’s Small Molecule Drug Discovery organization, rising to Senior Vice President after serving as Vice President of Discovery Chemistry. Under her leadership the group advanced more than 25 small-molecule clinical candidates across oncology, immunology, neuroscience, and infectious disease; she led the BTK-inhibitor program and co-invented fenebrutinib. Previously, she had scientific leadership roles at J&J and Axys/Celera Genomics. She currently works in venture creation and advises early-stage biotechs, including as an advisor at GV (Google Ventures) and is an independent board member at Rapport Therapeutics and several private biotechs. She was a Postdoctoral Fellow at Memorial Sloan Kettering Cencer Center and earned her Ph.D. from Princeton University and holds B.S. and M.S. degrees from Wake Forest University.